These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 17176247)

  • 1. Leukotriene B4 production in healthy subjects carrying variants of the arachidonate 5-lipoxygenase-activating protein gene associated with a risk of myocardial infarction.
    Maznyczka A; Mangino M; Whittaker A; Braund P; Palmer T; Tobin M; Goodall AH; Bradding P; Samani NJ
    Clin Sci (Lond); 2007 Jun; 112(7):411-6. PubMed ID: 17176247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic variants of arachidonate 5-lipoxygenase-activating protein, and risk of incident myocardial infarction and ischemic stroke: a nested case-control approach.
    Zee RY; Cheng S; Hegener HH; Erlich HA; Ridker PM
    Stroke; 2006 Aug; 37(8):2007-11. PubMed ID: 16778124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic variation in the arachidonate 5-lipoxygenase-activating protein (ALOX5AP) is associated with myocardial infarction in the German population.
    Linsel-Nitschke P; Götz A; Medack A; König IR; Bruse P; Lieb W; Mayer B; Stark K; Hengstenberg C; Fischer M; Baessler A; Ziegler A; Schunkert H; Erdmann J
    Clin Sci (Lond); 2008 Nov; 115(10):309-15. PubMed ID: 18318662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ALOX5AP gene variants and risk of coronary artery disease: an angiography-based study.
    Girelli D; Martinelli N; Trabetti E; Olivieri O; Cavallari U; Malerba G; Busti F; Friso S; Pizzolo F; Pignatti PF; Corrocher R
    Eur J Hum Genet; 2007 Sep; 15(9):959-66. PubMed ID: 17505527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke.
    Helgadottir A; Manolescu A; Thorleifsson G; Gretarsdottir S; Jonsdottir H; Thorsteinsdottir U; Samani NJ; Gudmundsson G; Grant SF; Thorgeirsson G; Sveinbjornsdottir S; Valdimarsson EM; Matthiasson SE; Johannsson H; Gudmundsdottir O; Gurney ME; Sainz J; Thorhallsdottir M; Andresdottir M; Frigge ML; Topol EJ; Kong A; Gudnason V; Hakonarson H; Gulcher JR; Stefansson K
    Nat Genet; 2004 Mar; 36(3):233-9. PubMed ID: 14770184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Arachidonate 5-lipoxygenase-activating protein (ALOX5AP) gene and coronary heart disease risk in familial hypercholesterolemia.
    van der Net JB; Versmissen J; Oosterveer DM; Defesche JC; Yazdanpanah M; Aouizerat BE; Steyerberg EW; Malloy MJ; Pullinger CR; Kane JP; Kastelein JJ; Sijbrands EJ
    Atherosclerosis; 2009 Apr; 203(2):472-8. PubMed ID: 18775537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between the gene encoding 5-lipoxygenase-activating protein and stroke replicated in a Scottish population.
    Helgadottir A; Gretarsdottir S; St Clair D; Manolescu A; Cheung J; Thorleifsson G; Pasdar A; Grant SF; Whalley LJ; Hakonarson H; Thorsteinsdottir U; Kong A; Gulcher J; Stefansson K; MacLeod MJ
    Am J Hum Genet; 2005 Mar; 76(3):505-9. PubMed ID: 15640973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Associations of genetic polymorphisms of arachidonate 5-lipoxygenase-activating protein with risk of coronary artery disease in a European-American population.
    Tsai AK; Li N; Hanson NQ; Tsai MY; Tang W
    Atherosclerosis; 2009 Dec; 207(2):487-91. PubMed ID: 19596330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation of the expression of 5-lipoxygenase-activating protein/5-lipoxygenase and the synthesis of leukotriene B(4) in osteoarthritic chondrocytes: role of transforming growth factor beta and eicosanoids.
    Martel-Pelletier J; Mineau F; Fahmi H; Laufer S; Reboul P; Boileau C; Lavigne M; Pelletier JP
    Arthritis Rheum; 2004 Dec; 50(12):3925-33. PubMed ID: 15593193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. No association of polymorphisms in the gene encoding 5-lipoxygenase-activating protein and myocardial infarction in a large central European population.
    Koch W; Hoppmann P; Mueller JC; Schömig A; Kastrati A
    Genet Med; 2007 Feb; 9(2):123-9. PubMed ID: 17304054
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human bronchial fibroblasts express the 5-lipoxygenase pathway.
    James AJ; Penrose JF; Cazaly AM; Holgate ST; Sampson AP
    Respir Res; 2006 Jul; 7(1):102. PubMed ID: 16872537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic variation in the leukotriene pathway is associated with myocardial infarction in the Chinese population.
    Li Y; Xu X; Zhang D; Cheng W; Zhang Y; Yu B; Zhang Y
    Lipids Health Dis; 2019 Jan; 18(1):25. PubMed ID: 30678701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancement of leukotriene B4 release in stimulated asthmatic neutrophils by platelet activating factor.
    Shindo K; Koide K; Fukumura M
    Thorax; 1997 Dec; 52(12):1024-9. PubMed ID: 9516893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic effects in the leukotriene biosynthesis pathway and association with atherosclerosis.
    Crosslin DR; Shah SH; Nelson SC; Haynes CS; Connelly JJ; Gadson S; Goldschmidt-Clermont PJ; Vance JM; Rose J; Granger CB; Seo D; Gregory SG; Kraus WE; Hauser ER
    Hum Genet; 2009 Mar; 125(2):217-29. PubMed ID: 19130089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. On the expression and regulation of 5-lipoxygenase in human lymphocytes.
    Jakobsson PJ; Steinhilber D; Odlander B; Rådmark O; Claesson HE; Samuelsson B
    Proc Natl Acad Sci U S A; 1992 Apr; 89(8):3521-5. PubMed ID: 1314391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperoxia increases protein mass of 5-lipoxygenase and its activating protein, flap, and leukotriene B(4) output in newborn rat lungs.
    Hosford GE; Koyanagi KS; Leung WI; Olson DM
    Exp Lung Res; 2002 Dec; 28(8):671-84. PubMed ID: 12490039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of a 5-lipoxygenase-activating protein inhibitor on biomarkers associated with risk of myocardial infarction: a randomized trial.
    Hakonarson H; Thorvaldsson S; Helgadottir A; Gudbjartsson D; Zink F; Andresdottir M; Manolescu A; Arnar DO; Andersen K; Sigurdsson A; Thorgeirsson G; Jonsson A; Agnarsson U; Bjornsdottir H; Gottskalksson G; Einarsson A; Gudmundsdottir H; Adalsteinsdottir AE; Gudmundsson K; Kristjansson K; Hardarson T; Kristinsson A; Topol EJ; Gulcher J; Kong A; Gurney M; Thorgeirsson G; Stefansson K
    JAMA; 2005 May; 293(18):2245-56. PubMed ID: 15886380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversal of human neutrophil survival by leukotriene B(4) receptor blockade and 5-lipoxygenase and 5-lipoxygenase activating protein inhibitors.
    Lee E; Lindo T; Jackson N; Meng-Choong L; Reynolds P; Hill A; Haswell M; Jackson S; Kilfeather S
    Am J Respir Crit Care Med; 1999 Dec; 160(6):2079-85. PubMed ID: 10588632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of neutrophil leukotriene B4 production by a novel synthetic N-3 polyunsaturated fatty acid analogue, beta-oxa 21:3n-3.
    Robinson BS; Rathjen DA; Trout NA; Easton CJ; Ferrante A
    J Immunol; 2003 Nov; 171(9):4773-9. PubMed ID: 14568954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of 5-lipoxygenase and biosynthesis of leukotriene B4 in human monomorphonuclear leukocytes.
    Claesson HE; Jakobsson PJ; Steinhilber D; Odlander B; Samuelsson B
    J Lipid Mediat; 1993; 6(1-3):15-22. PubMed ID: 8395238
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.